Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Fennec Pharmaceuticals Inc. FENC NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$18.00
+188%

Fennec Pharmaceuticals Inc. (FENC) is a Biotechnology company in the Healthcare sector, currently trading at $6.25. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is FENC = $18 (+188% upside).

Valuation: FENC trades at a trailing Price-to-Earnings (P/E) of -19.3 (S&P 500 average ~25).

Financials: revenue is $45M, +467.9%/yr average growth. Net income is $10M (loss), growing at -708%/yr. Net profit margin is -22.6% (negative). Gross margin is 91.6% (-2.8 pp trend).

Balance sheet: total debt is $0 against $35M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.34 (strong liquidity). Debt-to-assets is 0%. Total assets: $70M.

Analyst outlook: 7 / 7 analysts rate FENC as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 41/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

$18.00
▲ 188% Upside
Average Price Target
The 12-month price target for Fennec Pharmaceuticals Inc. is $18.00.

FENC SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 41/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — FENC

✓
VALUE Pass
100/100
FENC trades at a trailing Price-to-Earnings (P/E) of -19.3 (S&P 500 average ~25). Forward PEG -0.05 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.5. Analyst consensus target is $18, implying +188% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
FENC: +467.9%/yr revenue is, -708%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet FENC: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 6.34 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
41/100
FENC: Gross margin is 91.6% (-2.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 41/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 7 / 7 analysts rate FENC as buy (100%). Analyst consensus target is $18 (+188% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
FENC: Net profit margin is -22.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.68-9.92
Volume193.63K
Avg Volume (30D)166.71K
Market Cap$178.63M
Beta (1Y)0.93
Share Statistics
EPS (TTM)-0.36
Shares Outstanding$28.58M
IPO Date2017-09-15
Employees32
CEORobert C. Andrade
Financial Highlights & Ratios
Revenue (TTM)$45.42M
Gross Profit$41.59M
EBITDA$-6.86M
Net Income$-10.27M
Operating Income$-6.86M
Total Cash$36.72M
Net Debt$-36.72M
Total Assets$70.07M
Price / Earnings (P/E)-17.4
Price / Sales (P/S)3.93
Analyst Forecast
1Y Price Target$18.00
Target High$18.00
Target Low$18.00
Upside+188.0%
Rating ConsensusBuy
Analysts Covering7
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA31447P1009

Price Chart

Track all markets on TradingView
FENC
Fennec Pharmaceuticals Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
4.68 52WK RANGE 9.92

People Also View

EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 IRON
IRON
Disc Medicine, Inc.
$70.48
+2.95%
 HRMY
HRMY
Harmony Biosciences Holdings, Inc.
$29.29
+0.83%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.30
+2.32%
 JANX
JANX
Janux Therapeutics, Inc.
$15.24
+2.28%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 KROS
KROS
Keros Therapeutics, Inc.
$11.55
+3.59%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.87
+0.21%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message